Uterine Leiomyoma Competitive Landscape Research Report 2024: R&D Activities Stall with 12 Molecules in the Pipeline, Phase III Holds Only Three Drugs Whereas Phase II Holds Only Two Drugs

Disease Landscape - Uterine Leiomyoma (UL) is a significant health concern with over 16 million incident cases anticipated in 2024 across 16 countries [1] - Current treatment is dominated by gonadotropin-releasing hormone (GnRH) agonist drugs [1] - The disease landscape includes an overview of epidemiology, treatment options, and marketed products [11] Marketed Drugs Assessment - Leading marketed drugs are analyzed by mechanism of action, molecule type, and product profiles with sales forecasts [8] - The assessment provides insights into the annual cost of therapy and time to pricing and reimbursement [8] Pipeline Drugs Assessment - The UL pipeline is limited with only 12 molecules, including 3 in Phase III and 2 in Phase II [10] - Pipeline drugs are categorized by development stage, mechanism of action, molecule type, and route of administration [11] - Phase transition success rates (PTSR) and likelihood of approval (LoA) are evaluated for therapy areas and indications [7] Clinical Trials Assessment - Clinical trial activity is dominated by commercial sponsors, with the US emerging as a key country for trials [10] - Trials are analyzed by phase, status, virtual components, sponsors, geography, and endpoint status [14] - Enrollment analytics, site analytics, and feasibility analysis provide insights into trial conduct [14] Deals Landscape - Acquisitions have been the predominant type of deal in North America and Europe over the past decade [10] - Recent mergers, acquisitions, and strategic alliances are reviewed by region [12] Commercial Assessment - Key market players are identified, along with future market catalysts that could drive growth [4][13] - Strategies for in-licensing and out-licensing are developed through pipeline product reviews [11] - Business strategies are informed by trends shaping the UL market, including innovative products and technologies [11] Key Topics Covered - The report includes a comprehensive analysis of the UL market, from disease overview to commercial strategies [7] - It provides detailed insights into pricing, reimbursement, and the competitive landscape [7]